Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Market Closed
14 Feb, 06:57
XSHE XSHE
¥
29. 07
-0.58
-1.96%
¥
33.22B Market Cap
- P/E Ratio
2% Div Yield
8,636,090 Volume
- Eps
¥ 29.65
Previous Close
Day Range
28.96 30.05
Year Range
25.51 38.1

Summary

002294 closed yesterday lower at ¥29.07, a decrease of 1.96% from Thursday's close, completing a monthly decrease of -6.38% or ¥1.98. Over the past 12 months, 002294 stock lost -6.38%.
002294 is not paying dividends to its shareholders.
The last earnings report, released on Oct 21, 2024, exceeded the consensus estimates by 0.02%. On average, the company has surpassed earnings expectations by 0.05%, based on the last three reports.
Shenzhen Salubris Pharmaceuticals Co., Ltd. has completed 1 stock splits, with the recent split occurring on Apr 24, 2015.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XSHE (CNY).
Want to track 002294 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

002294 Chart

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) FAQ

What is the stock price today?

The current price is ¥29.07.

On which exchange is it traded?

Shenzhen Salubris Pharmaceuticals Co., Ltd. is listed on XSHE.

What is its stock symbol?

The ticker symbol is 002294.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 33.22B.

Has Shenzhen Salubris Pharmaceuticals Co., Ltd. ever had a stock split?

Shenzhen Salubris Pharmaceuticals Co., Ltd. had 1 splits and the recent split was on Apr 24, 2015.

Shenzhen Salubris Pharmaceuticals Co., Ltd. Profile

Medical Instruments & Supplies Industry
Healthcare Sector
Mr. Jie Yan CEO
XSHE Exchange
CNE100000FW8 ISIN
CN Country
3,517 Employees
- Last Dividend
24 Apr 2015 Last Split
10 Sep 2009 IPO Date

Overview

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a prominent pharmaceutical and medical device company based in Shenzhen, China. Since its incorporation in 1998, the company has been dedicated to the research, development, production, and sale of a wide range of medicines and medical devices. Operating as a subsidiary of Salubris Pharmaceuticals Co., Ltd., its extensive product portfolio spans various therapeutic fields, including thrombosis, hypertension, osteoporosis, infections, and more. Moreover, it has a strong commitment to innovation in the therapeutic areas of cardiovascular and cerebrovascular diseases through the development of interventional medical devices.

Products and Services

  • Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets

    These are all innovative medications currently in phase III clinical trials intended for the treatment of hypertension. Each drug demonstrates Shenzhen Salubris Pharmaceuticals Co., Ltd.'s expertise in developing effective therapies for managing blood pressure conditions.

  • Enarodustat

    A promising drug for the treatment of renal anemia, showcasing the company's commitment to addressing chronic kidney disease complications.

  • SAL056, SAL001, SAL023

    Medications in development for the treatment of osteoporosis, which highlight the company's focus on bone health and the prevention of bone-related diseases.

  • Fotagliptin and SAL015

    These are under phase III clinical trials for diabetes, indicating the company's involvement in the fight against this widespread metabolic disorder.

  • Sacubitril Allisartan Calcium and SAL007 for Chronic Heart Failure; SAL003 for Hypercholesterolemia; SAL0114 for Depressant Indications

    These medications, in various stages of development, demonstrate Shenzhen Salubris Pharmaceuticals' efforts to address critical aspects of cardiovascular health and mental well-being.

  • SAL023, SAL0112, and SAL008

    Preclinical products targeting osteoporosis, diabetes, and tumors, respectively, showing the broad scope of the company's research and development pursuits in critical health areas.

  • Intracranial Segment of Vertebral Artery Stent, SaExtenVena Cava Filter, Microneedle Perfusion Absolute Ethanol Delivery System, and LAMax LAAC Left Atrial Appendage Occluder

    These are among the interventional medical devices developed by the company. Ranging from neurology to peripheral vascular and structural heart disease interventions, these devices underscore Shenzhen Salubris Pharmaceuticals' innovation in medical technology to improve patient outcomes.

Contact Information

Address: Digital Peninsula, No. 289, No. 2 Hongliu Road, Shenzhen, China, 518017
Phone: 86 755 8386 7888